ViroPharma Incorporated / Lev Pharmaceuticals, Inc.

Hereditary Angioedema (HAE)

$600M Cinryze 10-year cumulative sales milestone threshold (per CVR)

Disease Overview

Hereditary angioedema (HAE) is a rare, autosomal-dominant genetic disorder caused by C1 esterase inhibitor deficiency, leading to uncontrolled bradykinin production and recurrent episodes of severe subcutaneous and submucosal swelling. Without treatment, laryngeal attacks can be fatal — historical mortality estimates approach 25%. Roughly 10,000 patients are affected in the US.

Competitive Landscape

At the July 2008 ViroPharma-Lev deal announcement, Cinryze (plasma-derived C1 esterase inhibitor) was the lead asset under FDA review, with PDUFA action expected October 14, 2008 — and the FDA did approve it in October 2008 for routine HAE prophylaxis with seven years of orphan exclusivity. The HAE landscape was rapidly opening up: CSL Behring's Berinert (acute attacks) followed in 2009, Shire's Firazyr (icatibant, bradykinin B2 antagonist) was approved in EU 2008 and US 2011, Dyax's Kalbitor (ecallantide, plasma kallikrein inhibitor) in 2009, and CSL's Haegarda subcutaneous C1-INH later in the cycle. The $442.9M upfront ($2.75/share = $2.25 cash + $0.50 stock) plus up to $1.00/share in CVRs (total potential $617.5M) reflected a 49% premium and was justified by Cinryze's orphan economics: ~10,000 US patients, urgent unmet need, and modest commercial infrastructure required. Crucially, ViroPharma was facing imminent generic competition to Vancocin (oral vancomycin), making Cinryze a portfolio-defining diversification. Cinryze later anchored Shire's $4.2B acquisition of ViroPharma in 2014.